Loading stock data…
$2.07+0.02 (+0.98%)
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
Nautilus Biotechnology, Inc. in the Healthcare sector is trading at $2.07 with a market capitalization of $115M. Wall Street consensus targets $3.83 (3 analysts), implying a +85.2% move over the next 12 months. The stock is currently 52% below its 52-week high of $4.31, remaining 0.0% below its 200-day moving average. On fundamentals, Piotroski 2/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 75 is overbought against a weak tape. The Whystock Score of 45/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10,000 | $0 | $0 | $0 | $0 |
| Gross Profit | -$5,000 | — | — | — | $0 |
| Operating Income | -$15.76M↑ | -$16.12M↓ | -$15.42M↑ | -$15.47M↑ | -$17.10M |
| Net Income | -$14.47M↑ | -$14.70M↓ | -$13.78M↓ | -$13.57M↑ | -$15.03M |
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, whic...